Every Form 4 that VYNE Therapeutics Inc. (VYNE) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow VYNE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VYNE filings page.
Yarrow Bioscience, Inc. reports that an affiliated RTW Entity managed by RTW Fund Group GP, LLC exchanged 133,290 shares of common stock for pre-funded warrants to purchase the same number of shares on July 29, 2026. Following this restructuring, the RTW Entity holds 8,949,719 pre-funded warrants and 266,307 common shares, all indirectly, with beneficial ownership disclaimed except to the extent of pecuniary interest. The pre-funded warrants have a $0.0001 exercise price, no expiration, and a 9.99% beneficial ownership cap.
Yarrow Bioscience, Inc. director Ashiya Mona reported a grant of stock options covering 15,435 shares of common stock on July 27, 2026. The options have a $28.5600 exercise price, expire on July 27, 2036, and vest in full on the earlier of July 27, 2027 or the next annual meeting of stockholders, subject to continued service. Under an agreement, Mona must transfer any securities issued, or their economic benefit, to OrbiMed Advisors LLC, which will provide them to OrbiMed Private Investments X, LP.
Zeronda Tyler, a director of Yarrow Bioscience, Inc., received a grant of stock options covering 185,798 shares of common stock on July 27, 2026. The options have an exercise price of $28.56 per share, expire on July 27, 2036, and vest one quarter on July 27, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to continued service.
VYNE Therapeutics Inc. reports that Chief Financial Officer Tyler Zeronda had 22,516 shares of common stock withheld on 2026-07-23 to satisfy tax withholding requirements arising from the vesting of restricted stock units, at $0.8976 per share. After this tax-withholding disposition, Zeronda directly holds 74,918 shares of VYNE common stock.
VYNE Therapeutics Inc. reported that Chief Scientific Officer Stuart Iain had 15,405 shares of common stock withheld on 2026-07-23 to satisfy tax withholding tied to vesting restricted stock units. The shares were valued at $0.8976 each, and he now holds 95,944 shares directly.
VYNE Therapeutics Inc.’s chief legal officer Mutya Harsch reported a tax-withholding share disposition. The issuer withheld 22,516 shares of common stock on July 23, 2026 at $0.8976 per share to satisfy tax obligations on vested restricted stock units. Harsch now directly holds 95,918 shares.
VYNE Therapeutics Inc. reports that President and CEO David Domzalski had 79,391 shares of Common Stock withheld by the issuer at $0.8976 per share to satisfy tax obligations related to the vesting of restricted stock units. After this tax-withholding disposition, he directly holds 347,174 shares.
VYNE Therapeutics Inc. chief financial officer Tyler Zeronda reported a routine tax-related share disposition. On June 30, 2026, 3,464 shares of common stock were withheld at $0.6507 per share to cover tax obligations arising from the vesting of restricted stock units. After this withholding, Zeronda directly held 97,434 shares of VYNE common stock, indicating the event was compensation- and tax-driven rather than an open-market sale.
VYNE Therapeutics’ Chief Scientific Officer Stuart Iain had 2,370 shares of Common Stock withheld by the company to cover taxes related to vesting restricted stock units. The shares were valued at $0.6507 each in this tax-withholding disposition.
After this routine, non-market transaction, Iain directly holds 111,349 shares of VYNE Therapeutics Common Stock. The filing reflects compensation-related share withholding rather than an open-market purchase or sale.
VYNE Therapeutics Inc.'s Chief Legal Officer and General Counsel, Mutya Harsch, reported a routine tax-related share disposition. On the vesting of restricted stock units, 3,464 shares of common stock were withheld by the company to cover tax withholding obligations at a value of $0.6507 per share. This was not an open-market trade. After this tax-withholding event, Harsch directly holds 118,434 shares of VYNE common stock.
VYNE Therapeutics president and CEO David Domzalski reported a routine tax-related share disposition. On the vesting of restricted stock units, 12,214 shares of common stock were withheld by the company to cover tax obligations at a price of $0.6507 per share. After this withholding, Domzalski directly holds 426,565 shares of VYNE common stock.
VYNE Therapeutics Inc. reported that President and CEO David Domzalski acquired additional common stock through the company’s employee share purchase plan. On May 29, he obtained 30,791 shares of common stock at a price of $0.31 per share, characterized as a grant or award acquisition rather than an open-market purchase. Following this transaction, his directly held position increased to 438,779 shares. The footnote explains these shares were bought under the ESPP for the purchase period from December 1, 2025 to May 31, 2026 at 85% of the fair market value closing price on December 1, 2025, and that he purchased the maximum number of shares permitted under the plan for the calendar year.
VYNE Therapeutics Chief Financial Officer Zeronda Tyler reported an automatic tax-related share disposition. On the vesting of restricted stock units, 4,007 shares of common stock were withheld by the company at $0.5975 per share to cover tax obligations. After this non-market transaction, Tyler directly holds 99,788 shares of VYNE common stock.
VYNE Therapeutics Inc.'s Chief Scientific Officer Stuart Iain reported a routine tax-related share disposition. On the vesting of restricted stock units, 2,876 shares of common stock were withheld by the company to satisfy tax withholding requirements at an indicated value of $0.5975 per share. After this non-market transaction, he directly holds 112,363 common shares, so the withholding reflects only a small portion of his overall position.
VYNE Therapeutics Inc. chief legal officer Harsch Mutya reported a tax-related share disposition. On the vesting of restricted stock units, 4,007 shares of common stock were withheld by the company at $0.5975 per share to satisfy tax withholding requirements.
After this withholding, Mutya directly holds 121,898 shares of VYNE common stock. The transaction is classified as a tax-withholding disposition rather than an open-market sale.
VYNE Therapeutics President and CEO David Domzalski had 14,232 shares of Common Stock withheld on March 31, 2026 to cover tax obligations from vesting restricted stock units. This was a tax-withholding disposition at $0.5975 per share, and he continues to hold 401,976 shares directly.
VYNE Therapeutics Inc. reported that one of its non-employee directors received an annual stock option award on December 12, 2025, the date of the company’s annual meeting of stockholders. The option covers 20,000 shares of VYNE common stock with an exercise price of $0.3756 per share and a stated expiration date of December 11, 2035.
According to the filing, the option vests in full on December 12, 2026, provided the director continues to serve through that date. After this grant, the director beneficially owns 20,000 derivative securities directly, reflecting this stock option position.
A director of VYNE Therapeutics Inc. reported receiving an annual grant of stock options for 20,000 shares of common stock on December 12, 2025. The options have an exercise price of $0.3756, expire on December 11, 2035, and relate to 20,000 shares. According to the filing, the options vest on December 12, 2026, if the director continues to provide service through that date.
VYNE Therapeutics Inc. disclosed that a non-employee director received an annual stock option award on 12/12/2025. The grant covers 20,000 stock options to purchase common stock at an exercise price of $0.3756 per share and expires on 12/11/2035.
The shares underlying the option vest on 12/12/2026, subject to the director’s continuous service through that date. Following this grant, the director beneficially owns 20,000 derivative securities directly.
VYNE Therapeutics Inc. reported that a non-employee director received an annual stock option award on December 12, 2025, the date of the company’s annual meeting of stockholders. The filing shows the grant of 20,000 stock options to purchase VYNE common stock at an exercise price of $0.3756 per share. These options vest on December 12, 2026, conditioned on the director’s continuous service through that date, and are scheduled to expire on December 11, 2035. Following this transaction, the director is shown as beneficially owning 20,000 derivative securities, all held directly.